Trial · NCT07901933
Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
NCT07901933, Phase 1, Not yet recruiting, Cajal Therapeutics Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease. Trials, record NCT07901933. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901933
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
- NCT number
- NCT07901933
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Cajal Therapeutics Inc.
- Conditions
- Chronic Kidney Disease, Anemia
- Interventions
- Placebo, CTX001, Ferrous Sulfate
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Treatment-Emergent Adverse Events (TEAEs) | From first administration of study intervention through the end of study participation, around Day 36. | Number and percentage of participants with at least one (TEAE). An adverse event (AE) is any untoward medical occurrence in a participant, whether or not considered related to the study intervention. An AE is considered a treatment-emergent AE (TEAE) if the AE begins or worsens after the first dose of study intervention and on or before the last study visit. |
| Primary | Incidence of Serious TEAEs | From first administration of study intervention through the end of study participation, around Day 36. | Number and percentage of participants with at least one serious treatment-emergent adverse event (TEAE). A serious AE (SAE) is defined as any AE that, at any dose, meets one or more of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital anomaly or birth defect; or any important medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above. |
| Primary | Incidence of Clinically Significant Changes in Physical Examination | From first administration of study intervention through the end of study participation, around Day 36. | The investigator assesses the clinical significance of changes in physical examination findings. |
| Primary | Incidence of Clinically Significant Changes in Safety Laboratory Values | From first administration of study intervention through the end of study participation, around Day 36. | Safety laboratory evaluations include blood counts, serum chemistries, coagulation studies and urinalyses. Determination of clinical significance is based on investigator discretion. |
| Primary | Incidence of Clinically Significant Changes in Vital Signs | From first administration of study intervention through the end of study participation, around Day 36 | Vital signs include heart rate, respiratory rate, blood pressure, and temperature. Determination of clinical significance is based on investigator discretion. |
| Primary | Incidence of Clinically Significant Changes in Electrocardiograms | From first administration of study intervention through the end of study participation, around Day 36 | Electrocardiograms are tests that measure the electrical activity of the heart. Determination of clinical significance is based on investigator discretion. |
| Secondary | Maximum Change From Baseline in Hemoglobin | From first administration of study intervention through the end of study participation, around Day 36 | Maximum observed change from baseline in hemoglobin concentration. |
| Secondary | Maximum Change From Baseline in Hematocrit | From first administration of study intervention through the end of study participation, around Day 36 | Maximum observed change from baseline in hematocrit. |
| Secondary | Maximum Change from Baseline in Serum Iron | Baseline through the end of the treatment period, around Day 29 | |
| Secondary | Maximum Change from Baseline in Ferritin | Baseline through the end of the treatment period, around Day 29 |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07901933
GET https://conductscience.org/api/trials/v1/NCT07901933/registered?page=2